WONDER DRUG CONSULTING - Key Persons
Job Titles:
- CEO
- Founder
- Independent Consultant
Michael gained his B.Sc (Hons) in Biochemistry & Pathology from the University of Melbourne and a B. Pharm. from the Victorian College of Pharmacy, before working as a hospital pharmacist for five years. He then moved to Novartis Pharmaceuticals Australia as their first Health Economics Manager, working on strategic development and preparation of reimbursement and/or pricing submissions, before being appointed Director of Global Pricing and Market Access Operations for Novartis Pharma AG.
Since 2011, Michael has been an independent consultant on biopharmaceutical reimbursement and pricing matters. He has also acted as an expert advisor to the Masters of Science in International Health Technology Assessment, Pricing and Reimbursement at the University of Sheffield and the Distance Learning Certificate Program in Health Economics and Outcomes Research at the University of Washington.
What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?
Wonder M, 2014. Expert Review of Pharmacoeconomics & Outcomes Research, volume: 12, Issue: 6, page/s: 1-3